Find Sparsentan manufacturers, exporters & distributors on PharmaCompass

Sparsentan

Sparsentan

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

3 API Suppliers, 1 NDC API, 3 Listed Suppliers

DEVELOPMENTS

24 Drug(s) in Development

24 Drug(s) in Development

DOSSIERs // Finished Dosage Formulations

2 Dossiers, 2 FDA Orange Book

MARKET PLACE

1 APIs

1 APIs

PATENTS

2 US Patents, 4 US Exclusivities

DIGITAL CONTENT

25 News

25 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 254740-64-2, Sparsentan (re-021), Re-021, Sparsentan [usan], Ps433540, Ps-433540

Molecular Formula

C₃₂H₄₀N₄O₅S

Molecular Weight

592.8 g/mol

InChI Key

WRFHGDPIDHPWIQ-UHFFFAOYSA-N

FDA UNII

9242RO5URM

Sparsentan has been used in trials studying the treatment of Focal Segmental Glomerulosclerosis. Sparsentan is the first and only dual-acting angiotensin and endothelin receptor antagonist (DARA) in development.

1 2D Structure

Sparsentan

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide

2.1.2 InChI

InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)

2.1.3 InChI Key

WRFHGDPIDHPWIQ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC

2.2 Other Identifiers

2.2.1 UNII

9242RO5URM

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (1,1'-biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-

2. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide

3. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide

4. Re-021

2.3.2 Depositor-Supplied Synonyms

1. 254740-64-2

2. Sparsentan (re-021)

3. Re-021

4. Sparsentan [usan]

5. Ps433540

6. Ps-433540

7. 9242ro5urm

8. Chembl539423

9. 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide

10. 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-n-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide

11. Retrophin

12. (1,1'-biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-

13. [1,1'-biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-

14. Unii-9242ro5urm

15. Dara

16. Compound 7 [pmid 15634011]

17. Dara-a

18. Ps 33540

19. Sparsentan [inn]

20. Sparsentan (usan/inn)

21. Sparsentan(ps433540)

22. Sparsentan [who-dd]

23. Schembl535109

24. Gtpl8448

25. Amy38147

26. Bcp23969

27. Ex-a3048

28. Bdbm50175523

29. S6665

30. Cs-7947

31. Db12548

32. Sb16876

33. Dara-a (dual Acting Receptor Antagonist Of Angiotension And Endothelin Receptors)

34. Ps-433540;re-021;dara

35. Ac-35179

36. Hy-17621

37. Sparsentan (ps-433540,re-021,dara)

38. D11776

39. F77045

40. A858308

41. L023324

42. Q27088845

43. 4''''-(2-butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''''-ethoxymethyl-biphenyl-2-sulfonic Acid (4,5-dimethyl-isoxazol-3-yl)-amide

44. 4''-(2-butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''-ethoxymethyl-biphenyl-2-sulfonic Acid (4,5-dimethyl-isoxazol-3-yl)-amide

45. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyi)-n-(4,5- Dimethylisoxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide

46. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide

47. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₃₂H₄₀N₄O₅S
Molecular Weight	592.8 g/mol
XLogP3	5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	12
Exact Mass	592.27194156 g/mol
Monoisotopic Mass	592.27194156 g/mol
Topological Polar Surface Area	123 Å²
Heavy Atom Count	42
Formal Charge	0
Complexity	1060
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of focal segmental glomerulosclerosis

Treatment of primary IgA nephropathy

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

Sparsentan, which possesses two clinically validated mechanisms of action in a single molecule, works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Sparsentan is highly selective (10,000-fold) for the AII receptor sub-type 1 and the ET receptor sub-type A. As such, Sparsentan combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule.